The company has recently raised SEK 10 million in directed issue for a novel obesity-related study. The aim is to study drug tolerance and the effects of the company’s molecule
Nordic Life Science
Advertisement
NLS News
IRLAB Therapeutics has announced that the company has been granted a new patent in Europe, which includes a new salt of mesdopetam used throughout the clinical development process and the
In a recent study published in Nature, Swedish researchers demonstrate the role of sex hormones in regulating the immune system. This newfound knowledge explains differences between men and women and
Advertisement
The European Commission has granted Orphan Medicinal Product Designation (OMPD) to the company’s lead drug candidate CS1 in the rare disease Pulmonary Arterial Hypertension (PAH). “This designation offers significant advantages,
The Theranostics Trial Center (TTC) at Karolinska University Hospital has been awarded financing from Vinnova to run a new project in precision medicine. By combining image-guided diagnostics and therapy with
Business Region Göteborg and AstraZeneca have entered a strategic collaboration with the aim to further strengthen the entire life science sector and create jobs and growth in the region. “In
Nobel Prize in Medicine
Professor Honjo did not set out to find a cure for cancer but he is glad he did not give up and believes cancer immunotherapy will be the Number One
When your passion and lifelong work are the same. Great things can happen. Just ask James Allison.
The 2018 Nobel Prize in Medicine was awarded to James P. Allison and Tasuku Honjo for ther pioneering work in cancer immunotheraphy.
“Immunotherapy can be combined with almost anything; you can combine it with chemotherapy or radiation as long as you do it right. The benefits of immunotherapy are several; the best one is that once T cells see something different about the cancer cell and attack the cancer, they can be re-activated [if the cancer reoccurs.]” – James Allison
Drug & Device development
In a new publication in “Vaccines” from Department of Immunology and Microbiology, Centre for translational Medicine & Parasitology at Copenhagen University, Attana’s technology has been applied to determine the interaction
“The risks involved in investing in drug development for neurological and psychiatric diseases are high, as these are difficult-to-measure conditions and trial have had high failure rates. In cancer there
Verrica Pharmaceuticals reports results from its study investigating Lytix’s lead drug candidate LTX-315 in patients with basal cell carcinoma (BCC). In short, the result showed that 86 percent overall reduction
Affibody’s partner ACELYRIN has announced that the Phase 3 trial of the Affibody molecule izokibep in patients with hidradenitis suppurativa (HS) achieved its primary endpoint of HiSCR75 at 12 weeks, as
A commercially available blood test has now been trialled in routine healthcare. “The blood test showed about 90% reliability even in primary care. This may have major implications for all
TikoMed has announced the publication in PLOS ONE of peer-reviewed research providing additional support that their low molecular weight dextran sulfate compound ILB is safe and well tolerated in patients
Global Report
Pharmaceuticals in the environment is a growing problem of global concern. Drugs taken by humans and animals find their way into rivers, lakes and even drinking water and can have
Pharmaceutical waste
Nordic efforts to prevent pharmaceuticals affecting the environment include Danish management of hospital wastewater and a Swedish large-scale sewage plant for removal of pharmaceutical residues. Wastewater from hospitals can contain
Nobel Prize in Medicine
Professor Honjo did not set out to find a cure for cancer but he is glad he did not give up and believes cancer immunotherapy will be the Number One
The company has recently raised SEK 10 million in directed issue for a novel obesity-related study. The aim is to study drug tolerance and the effects of the company’s molecule
Latest news
“The risks involved in investing in drug development for neurological and psychiatric diseases are high, as these are difficult-to-measure conditions and trial have had high failure rates. In cancer there
Advertising
[aas_zone zone_id=”7910″]
[aas_zone zone_id=”7909″]
[aas_zone zone_id=”7915″]
[aas_zone zone_id=”8010″]
[aas_zone zone_id=”7913″]
Our region is filled with life science activity. We take a closer look at what´s going in our Nordic cities when it comes to life science efforts, progress and challenges.
In focus – Nordic cities
Nordic Life Science
The latest clinical trials
“The risks involved in investing in drug development for neurological and psychiatric diseases are high, as these are difficult-to-measure conditions and trial have had high failure rates. In cancer there
Verrica Pharmaceuticals reports results from its study investigating Lytix’s lead drug candidate LTX-315 in patients with basal cell carcinoma (BCC). In short, the result showed that 86 percent overall reduction
Affibody’s partner ACELYRIN has announced that the Phase 3 trial of the Affibody molecule izokibep in patients with hidradenitis suppurativa (HS) achieved its primary endpoint of HiSCR75 at 12 weeks, as
TikoMed has announced the publication in PLOS ONE of peer-reviewed research providing additional support that their low molecular weight dextran sulfate compound ILB is safe and well tolerated in patients
The topline data readout from the Phase II FOCUS trial demonstrated that adding UV1 to the standard of care pembrolizumab did not lead to clinical benefits in progression free survival
Diamyd Medical has announced a successful interim analysis (non-futility test) for its ongoing precision medicine Phase 3 DIAGNODE-3 trial. The interim analysis, reviewed by an independent Data Safety Monitoring Board
Medivir has presented new data from its ongoing phase Ib/IIa study of fostroxacitabine bralpamide (fostrox) + Lenvima in advanced hepatocellular carcinoma (HCC) at the European Society of Medical Oncology, Gastrointestinal
Alligator Bioscience has announced positive 18-month follow-up data from the OPTIMIZE-1 Phase 2 study of the company’s lead asset mitazalimab in 1st line metastatic pancreatic cancer. The open-label, multi-center study
The latest research news from the Nordic region
Science Article
In a recent study published in Nature, Swedish researchers demonstrate the role of sex hormones in regulating the immune system. This newfound knowledge explains differences between men and women and
A commercially available blood test has now been trialled in routine healthcare. “The blood test showed about 90% reliability even in primary care. This may have major implications for all
A new study from deCODE genetics and collaborators is the first to uncover a strong recessive component in Alzheimer’s disease. deCODE genetics/Amgen, and collaborators from Iceland, USA, UK, Denmark, Norway,
Botond Roska and José-Alain Sahel have been awarded the Wolf Prize in Medicine for their pioneering work on restoring vision to blind patients using optogenetic therapy. The Wolf Prize recognizes
Unfortunately genes do matter when it comes to obesity, but knowledge about these genes and how they work are key to improving treatment and prevention. “Over the past two decades,
Professor Hindrik Mulder’s research on islet cells and his commitment to the scientific community have been recognized as he receives the 2024 Novo Nordisk Foundation Lecture Prize, which comes with
Sign up to our newsletter
Advertisement
